Search Results - "Garrigue, V."

Propensity score–based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors by Querard, A. H., Le Borgne, F., Dion, A., Giral, M., Mourad, G., Garrigue, V., Rostaing, L., Kamar, N., Loupy, A., Legendre, C., Morelon, E., Buron, F., Foucher, Y., Dantan, E.

“…From a prospective and multicentric French cohort, we proposed an external validation study for the expanded criteria donor (ECD), based on 4833 kidney…”
Get full text

Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients by Alméras, C., Vetromile, F., Garrigue, V., Szwarc, I., Foulongne, V., Mourad, G.

“…C. Alméras, F. Vetromile, V. Garrigue, I. Szwarc, V. Foulongne, G. Mourad. Monthly screening for BK viremia is an effective strategy to prevent BK virus…”
Get full text

Early Corticosteroid Avoidance in Kidney Transplant Recipients Receiving ATG‐F Induction: 5‐Year Actual Results of a Prospective and Randomized Study by Cantarovich, D., Rostaing, L., Kamar, N., Ducloux, D., Saint‐Hillier, Y., Mourad, G., Garrigue, V., Wolf, P., Ellero, B., Cassuto, E., Albano, L., Völp, A., Soulillou, J.‐P.

“…One hundred ninety‐seven patients received anti‐T‐lymphocyte globulins Fresenius, mycophenolate mofetil and delayed cyclosporine, and were randomized to…”
Get full text

Renal Transplantation in Patients With AA Amyloidosis Nephropathy: Results From a French Multicenter Study by Kofman, T., Grimbert, P., Canouï‐Poitrine, F., Zuber, J., Garrigue, V., Mousson, C., Frimat, L., Kamar, N., Couvrat, G., Bouvier, N., Albano, L., Le Thuaut, A., Pillebout, E., Choukroun, G., Couzi, L., Peltier, J., Mariat, C., Delahousse, M., Buchler, M., Le Pogamp, P., Bridoux, F., Pouteil‐Noble, C., Lang, P., Audard, V.

“…Although end‐stage renal disease related to AA amyloidosis nephropathy is well characterized, there are limited data concerning patient and graft outcome after…”
Get full text

Treatment Response and Outcomes in Post-transplantation Lymphoproliferative Disease vs Lymphoma in Immunocompetent Patients by Trusson, R, Serre, J.E, Szwarc, I, Brunot, V, Garrigue, V, Delmas, S, Kanouni, T, Cartron, G, Mourad, G

“…Abstract Posttransplantation lymphoproliferative disorder (PTLD) after solid organ transplantation may carry a poorer prognosis than lymphoma in…”
Get full text

Impact of Early or Delayed Cyclosporine on Delayed Graft Function in Renal Transplant Recipients: A Randomized, Multicenter Study by Kamar, N., Garrigue, V., Karras, A., Mourad, G., Lefrançois, N., Charpentier, B., Legendre, C., Rostaing, L.

“…The benefit of delayed cyclosporine in reducing risk of delayed graft function (DGF) is not clearly established. This study compared early vs. delayed…”
Get full text

An Epidemic of Pneumocystis Jiroveci Pneumonia in a Renal Transplantation Center: Role of T-Cell Lymphopenia by Brunot, V, Pernin, V, Chartier, C, Garrigue, V, Vetromile, F, Szwarc, I, Delmas, S, Portalès, P, Basset, D, Mourad, G

“…Abstract Although only 2 cases of Pneumocystis jiroveci pneumonia were observed in our center between 2004 and 2009, we diagnosed 9 cases in 2010. Each patient…”
Get full text

Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients by LEGENDRE, C, GARRIGUE, V, LE BIHAN, C, MAMZER-BRUNEEL, M. F, CHAIX, M. L, LANDAIS, P, KREIS, H, POL, A. S

“…The long-term impact of hepatitis C virus (HCV) infection in renal transplant recipients remains controversial. We report here our experience, in a homogeneous…”
Get full text

Evolution of Coronary Artery Calcifications Following Kidney Transplantation: Relationship with Osteoprotegerin Levels by Bargnoux, A.‐S., Dupuy, A.‐M., Garrigue, V., Jaussent, I., Gahide, G., Badiou, S., Szwarc, I., Deleuze, S., Vernhet, H., Cristol, J.‐P., Mourad, G.

“…We prospectively assessed the evolution of coronary artery calcification (CAC) and osteoprotegerin (OPG) levels after renal transplantation (RT). Eighty‐three…”
Get full text

Return to Dialysis After Renal Allograft Loss: Is Dialysis Treatment Initiated Too Late? by Sleiman, J, Garrigue, V, Vetromile, F, Mourad, G

“…Abstract Introduction Allograft failure is a common complication after renal transplantation. However, data describing the level of renal function and the…”
Get full text

Accuracy of GFR predictive equations in renal transplantation: Validation of a new turbidimetric cystatin C assay on Architect c8000 by Bargnoux, A.S., Servel, A.C., Piéroni, L., Dupuy, A.M., Badiou, S., Garrigue, V., Mourad, G., Cristol, J.P.

“…To evaluate the Sentinel-PETIA cystatin C on Architect c8000® analyzer. We assessed analytical performances and clinical relevance by comparison with a…”
Get full text

129 PREDICTIVE FACTORS, NATURAL HISTORY AND OUTCOME OF CHRONIC HEPATITIS E VIRUS INFECTION IN SOLID-ORGAN-TRANSPLANT PATIENTS: A RETROSPECTIVE MULTICENTER STUDY by Kamar, N, Haagsma, E.B, Garrigue, V, Pischke, S, Chauvet, C, Dumortier, J, Cannesson, A, Cassuto-Viguier, E, Thervet, E, Conti, F, Lebray, P, Dalton, H.R, Santella, R, Kanaan, N, Essig, M, Mousson, C, Radenne, S, Roque-Afonso, A.M, Izopet, J, Rostaing, L

Get full text

New Onset Dyslipidemia After Renal Transplantation: Is There a Difference Between Tacrolimus and Cyclosporine? by Deleuze, S., Garrigue, V., Delmas, S., Chong, G., Swarcz, I., Cristol, J.P., Mourad, G.

“…Lipid abnormalities including increased total cholesterol (TC), triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) have been frequently…”
Get full text

Small Dense Low-Density Lipoprotein in Renal Transplant Recipients: A Potential Target for Prevention of Cardiovascular Complications? by Badiou, S., Garrigue, V., Dupuy, A.M., Chong, G., Cristol, J.P., Mourad, G.

“…Immunosuppressive therapy is frequently associated with dyslipidemia, which is involved in cardiovascular morbidity and mortality in transplant patients…”
Get full text

Renal Transplantation Decreases Osteoprotegerin Levels by Bargnoux, A.S., Dupuy, A.M., Garrigue, V., Deleuze, S., Cristol, J.P., Mourad, G.

“…Vascular calcifications are an important risk factor for cardiovascular mortality and morbidity in patients with chronic renal failure. Osteoprotegerin, a…”
Get full text

Myocardial involvement in fibrinogen A–alpha chain amyloidosis by Gahide, G, Roubille, F, Macia, J.C, Garrigue, V, Vernhet, H

Get full text

Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication? by Garrigue, V, Canet, S, Dereure, O, Panabieres, O, Augias, D, Chong, G, Mourad, G

Get full text

Sirolimus-Associated Acute Respiratory Distress Syndrome in a Renal Transplant Recipient by Amigues, L., Klouche, K., Massanet, P., Gaillard, N., Garrigue, V., Beraud, J.-J., Mourad, G.

“…Sirolimus is a new potent immunosuppressive drug used in organ transplantation; its major advantage is the absence of deterioration in renal function…”
Get full text

Evaluation of an Immunoassay (Abbott-IMX Analyzer) Allowing Routine Determination of Sirolimus: Comparison With LC-MS Method by Bargnoux, A.S., Bonardet, A., Chong, G., Garrigue, V., Deleuze, S., Dupuy, A.M., Mourad, G., Cristol, J.P.

“…The use of the immunosuppressive agent sirolimus is increasing in renal transplantation but its monitoring often requires high-performance liquid…”
Get full text

Tolerability of Enteric-Coated Mycophenolate Sodium to 1 Year in Combination With Cyclosporine and Corticosteroids in Renal Transplant Recipients by Rostaing, L., Mourad, G., Kamar, N., Garrigue, V., Karras, A., Lefrançois, N., Charpentier, B., Bourbigot, B., Pouteil-Noble, C., Bayle, F., Lebranchu, Y., Berthoux, F., Le Meur, Y., Kessler, M., Moulin, B., Ducloux, D., Delahousse, M., Lang, P., Merville, P., Chaouche-Teyara, K., Legendre, C.

“…Enteric-coated mycophenolate sodium (EC-MPS) is therapeutically equivalent to mycophenolate mofetil, but delays release of mycophenolic acid until it reaches…”
Get full text